Recently released research from the Lewis Katz School of Medicine suggests that a cannabidiol-like molecule may be effective at treating pain resulting from chemotherapy.

A research team led by Sara Jane Ward, a professor of pharmacology, found certain applications of KLS-13019, a molecule developed by KannaLife Sciences, Inc., a biopharmaceutical company, might reverse pain from chemotherapy-induced neuropathy, or CIPN.